comparemela.com

Page 4 - நாசி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lobe Sciences Ltd : Lobe Sciences Successfully Completes Proof-of-Concept of Proprietary Nasal Mist Device

Lobe Sciences Ltd.: Lobe Sciences Successfully Completes Proof-of-Concept of Proprietary Nasal Mist Device Vancouver, British Columbia (Newsfile Corp. - February 18, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ( Lobe or the Company ) announced today the completion and testing of the proof-of-concept prototype of its proprietary nasal mist device. As announced on December 3, 2020, the Company engaged VisionWorks Engineering of San Diego, CA to complete this first phase of development. Lobe s nasal mist device delivers micro doses of pharmaceutical agents such as a psilocybin and N-acetylcysteine ( NAC ) at preselected dosages. Philip Young, CEO of Lobe states Advancing through the initial development and testing of our innovative nasal mist device will position Lobe as the leader in the delivery of effective therapeutics to treat patients suffering from mild traumatic brain injury, post-traumatic stress disorder, and other mental health conditions. We intend

SaNOtize Research and Development Corp : Covid-busting Nasal Spray Begins UK Trials January 11th

SaNOtize Research and Development Corp.: Covid-busting Nasal Spray Begins UK Trials January 11th Nasal spray blocks viral entry into the body, destroys virus and prevents it from multiplying Nitric oxide blocks ACE-2 receptor essential for the virus to infect cells, destroys Covid mutant variations Clinical trials already underway in Canada and approved to start in the USA London University professor conducting trial hopes for significant advance in our therapeutic armoury against this devastating disease The first UK clinical trials of a nasal spray proven to kill 99.9% of the coronavirus that causes Covid-19 will begin on January 11th at Ashford and St Peter s Hospitals NHS Foundation Trust, in Surrey.

Technavio Research: Global External Nasal Dilator Market to Grow by $ 102 41 Million During 2020-2024 | Featuring GlaxoSmithKline Plc, HealthRight Products LLC, and Walmart Inc among others

(1) Technavio estimates the global external nasal dilator market to grow by USD 102.41 million, progressing at a CAGR of over 4% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201230005392/en/ Technavio has announced its latest market research report titled Global External Nasal Dilator Market 2020-2024 (Graphic: Business Wire) The market is driven by increasing air pollution. In addition, the increasing severity of OSA is expected to further boost the market growth over the forecast period.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.